Effect of entacapone on plasma homocysteine levels in Parkinson’s disease patients

被引：0
作者：
Martin Nevrly
Petr Kanovsky
Hana Vranova
Katerina Langova
Petr Hlustik
机构：
[1] University Hospital and Palacký University Medical School,Department of Neurology
[2] Palacký University Medical School,Department of Biophysics
来源：
Neurological Sciences | 2010年 / 31卷
关键词：
Homocysteine; Parkinson’s disease; Entacapone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Peripheral metabolism of l-DOPA via enzyme catechol-O-methyltransferase (COMT) is one of the possible sources of homocysteine (HCY). The aim of this study was to assess plasma HCY levels in l-DOPA-treated Parkinson’s disease (PD) patients and its influence by adding the inhibitor COMT (entacapone). Patients were divided into two groups: (1) patients long term treated with l-DOPA but were naïve to entacapone, (2) l-DOPA naïve patients, in whom a combined treatment with l-DOPA and entacapone was started. The HCY levels were higher in Group 1 than in Group 2. No statistically significant changes of HCY concentrations were found in both patient groups after adding entacapone to their l-DOPA treatments. Results of this study confirm that patients treated with l-DOPA for a long term have increased plasma HCY concentrations. We believe combined l-DOPA and entacapone therapy could be a possible protective mechanism against hyperhomocysteinemia in early PD.
引用
收藏
页码：565 / 569
页数：4
相关论文
共 111 条
[21]  
Louis ED(1999)The effect of entacapone on homocysteine levels in Parkinson disease Annu Rev Nutr 19 217-1543
[22]  
Rektorová I(2008)The metabolism of homocysteine: pathways and regulation Am J Hum Genet 63 1541-1136
[23]  
Valkovič P(1991)Homocysteine metabolism Arterioscler Thromb 11 1129-399
[24]  
Blažíček P(2002)Measurement and use of total plasma homocysteine Cardiovasc Drugs Ther 16 391-291
[25]  
Benetin J(1995)Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease N Engl J Med 332 286-1403
[26]  
Kukumberg P(2003)Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins Clin Chem Lab Med 41 1392-146
[27]  
Blandini F(2003)Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis Trends Neurosci 26 137-529
[28]  
Fancellu R(1995)DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations Neurotoxicology 16 527-227
[29]  
Martignoni E(1998)Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders Eur Neurol 40 225-413
[30]  
Miller JW(2002)Sulfate and cysteine levels in the plasma of patients with Parkinson’s disease Nutr Rev 60 410-23
12345678910